Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Ventas, Raises Price Target to $54

Morgan Stanley Maintains Equal-Weight on Ventas, Raises Price Target to $54

Morgan Stanley analyst Richard Hill maintains Ventas (NYSE:VTR) with a Equal-Weight and raises the price target from $52 to $54.

byBenzinga Newsdesk

August 31, 2022

1 minute read

Morgan Stanley analyst Richard Hill maintains Ventas (NYSE:VTR) with a Equal-Weight and raises the price target from $52 to $54.

Performance Comparison: Meta Platforms And Competitors In Interactive Media & Services Industry

By Benzinga Insights

May 24, 11:00 AM

In today’s rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to…

Despite FDA Doubts, Adcomm Backs Alnylam’s Gene Silencing Therapy For Expanded Use Into Rare Heart Disease

By Vandana Singh

September 14, 7:26 AM

On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.

ALNY

Here’s How Much $1000 Invested In Target 5 Years Ago Would Be Worth Today

By Benzinga Insights

August 29, 3:41 PM

Target (NYSE:TGT) has outperformed the market over the past 5 years by 12.93% on an annualized basis producing an average annual return of 23.25%. Currently, Target has a market capitalization of $73.61 billion.

TGT

News

Sonim Technologies Announces Trade Agreements Act Compliant Manufacturing For New 5G Connected Solutions Portfolio

By Benzinga Newsdesk

June 4, 8:29 AM

Select products achieve Trade Agreements Act (TAA) compliance; unlocks new market opportunities and enhances operational resilienceSan Diego, California--(Newsfile Corp. - June 4, 2024) - Sonim Technologies, Inc.

SONM

Morgan Stanley Maintains Equal-Weight on Ventas, Raises Price Target to $54

Related Posts

Performance Comparison: Meta Platforms And Competitors In Interactive Media & Services Industry

Despite FDA Doubts, Adcomm Backs Alnylam’s Gene Silencing Therapy For Expanded Use Into Rare Heart Disease

Here’s How Much $1000 Invested In Target 5 Years Ago Would Be Worth Today

Sonim Technologies Announces Trade Agreements Act Compliant Manufacturing For New 5G Connected Solutions Portfolio